Memantine

Memantine hydrochloride is a raw material. It should be prescribed by experienced doctors in the diagnosis and treatment of Alzheimer's dementia and guided by patients. Treatment can only begin when there are caregivers around the patient who regularly supervise the patient's medication. Dementia should be diagnosed in accordance with current diagnostic criteria and guidelines.

Memantine is a medication used to treat moderate-to-severe Alzheimer's disease. It is less preferred than acetylcholinesterase inhibitors such as donepezil. Treatment should only be continued if beneficial effects are seen. It is taken by mouth.
Memantine was approved for medical use in the United States in 2003. It is available as a generic medication. In 2017, it was the 149th most commonly prescribed medication in the United States, with more than four million prescriptions

Memantine is clinically used for the treatment of moderate to severe senile dementia and parkinsonism syndrome. It is a new type of anti-senile dementia drug and can be used for the treatment of moderate to severe senile dementia.

Memantine is used to treat moderate-to-severe Alzheimer's disease, especially for people who are intolerant of or have a contraindication to AChE (acetylcholinesterase) inhibitors.One guideline recommends memantine or an AChE inhibitor be considered in people in the early-to-mid stage of dementia.

Memantine has been associated with a modest improvement; with small positive effects on cognition, mood, behavior, and the ability to perform daily activities in moderate-to-severe Alzheimer's disease. There does not appear to be any benefit in mild disease.

Memantine when added to donepezil in those with moderate-to-severe dementia resulted in "limited improvements" in a 2017 review. The UK National Institute of Clinical Excellence (NICE) issued guidance in 2018 recommending consideration of the combination of memantine with donepezil in those with moderate-to-severe dementia. Effects in autism are unclear. Recent scientific journal reports are showing guarded promise with severe obsessive compulsive disorder.

A ni ọpọlọpọ awọn ile-iṣelọpọ giga-giga pẹlu ifowosowopo jinlẹ, eyiti o le fun ọ ni awọn ọja to gaju ati awọn idiyele ifigagbaga. Ati pe a tun le fun awọn ẹdinwo fun awọn rira olopobobo.Ati pe a ṣe ifọwọsowọpọ pẹlu ọpọlọpọ awọn ile-iṣẹ gbigbe ẹru ẹru ọjọgbọn, le fi awọn ọja ranṣẹ lailewu ati laisiyonu si ọwọ rẹ. Akoko ifijiṣẹ jẹ nipa awọn ọjọ 3-20 lẹhin ijẹrisi isanwo.

Memantine is a medication used to treat moderate-to-severe Alzheimer's disease. It is less preferred than acetylcholinesterase inhibitors such as donepezil. Treatment should only be continued if beneficial effects are seen. It is taken by mouth.
Memantine was approved for medical use in the United States in 2003. It is available as a generic medication. In 2017, it was the 149th most commonly prescribed medication in the United States, with more than four million prescriptions

Memantine HCl is the HCl form of Memantine. Memantine is a well- known neuroprotective drug used for the treatment of Alzheimer's disease. It is believed to be the first neuroprotective drug that has achieve clinical approval by US FDA as well as European.
The development of Alzheimer's disease involves the misfolded mutant proteins such as β-amyloid peptide (Aβ, particularly Aβ1−42). These misfolded mutant protein can increase the NMDA response and further cause severe excitotoxicity.
Memantine suppresses this process through acting as the antagonist of the N-methyl-d- aspartate-sensitive glutamate receptor (NMDARs).
Memantine is also under investigation as a potential treatment for other kind of neurodegenerative disorders such as HIV-associated dementia, neuropathic pain, glaucoma, depression, Huntington's disease, ALS and movement disorders, among other. 

1. Ṣe o jẹ ile-iṣẹ tabi ile-iṣẹ iṣowo kan?
A jẹ ile-iṣẹ iṣọpọ compnay ati iṣowo, ti n pese iṣẹ iduro kan.OEM le gba.

2. Ṣe o pese awọn ayẹwo? Ṣe o jẹ ọfẹ tabi afikun?
Awọn ayẹwo ọfẹ.Ọya ẹru ọkọ ayẹwo naa nilo lati san nipasẹ ẹgbẹ rẹ.

3. Ṣe o ni awọn iwe-ẹri eyikeyi ti o ni ibatan si iṣakoso didara?
ISO 9001: 2008 iwe-ẹri lati rii daju didara.

4. Kini MO yẹ ki n pese lati gba agbasọ ọrọ kan?
Pls sọ fun wa iru ọja ti o nilo, iwọn ibere, adirẹsi ati awọn ibeere pataki.Itọkasi yoo ṣee ṣe fun itọkasi rẹ ni akoko.

5. Iru ọna sisan wo ni o fẹ? Iru awọn ofin wo ni a gba?
Awọn ofin Ifijiṣẹ ti a gba: FOB, CFR, CIF, EXW;
Ti gba Owo Isanwo:USD;
Ti gba Isanwo Isanwo: T/T,Western Union; Paypal, Iṣowo Iṣowo.
Ede Sọ: Gẹẹsi.